ARTHROPLASTY
AAOS 2015: No difference between topical and intravenous tranexamic acid for TKA
131 patients undergoing total knee arthroplasty were randomized to receive tranexamic acid either topically, with 2mg injected intra-articularly following capsular closure, or 1 mg intravenously prior to tourniquet inflation and another 1mg prior to tourniquet deflation. Postoperative hemoglobin levels and cumulative blood loss were assessed for 3 days postoperatively, and length of stay, discharge location, and complication rates were recored. There were no observed significant differences between the two groups in any of the outcomes assessed.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
